Another interesting, alternative approach to achieve atheroprotective immune modulation was the LILACS trial (Low-Dose Interleukin-2 in Patients with Stable Ischemic Heart Disease and Acute Coronary Syndromes) that aimed to study the effect of increasing Treg cells by treatment with low dose IL-2 [50,51]. Here, IL2 is linked to acute coronary syndrome.